AIM ImmunoTech Inc: Meet the team behind the drug that put a 90% dent in COVID-19 infection

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) is one of five biopharma companies presenting at Proactive’s online event on September 10 – all of them are playing a role to combat COVID-19. The event kicks off at 1 pm EDT on Thursday, September 10. This is an online variant of the popular conference format Proactive has run for more than a decade and enables communication between investors and management from some of the world's cutting-edge businesses. SIGN-UP: Proactive One2One September 10, 1pm Florida-based AIM ImmunoTech has ordinarily focussed on the research into the treatment of immune disorders, and it has developed the drug Ampligen which according to a study can decrease the infectious viral yield of SARS-CoV-2 by 90% (in a recent in vitro model). The company has decided to test Ampligen in humans – a trial is slated to begin patient enrolment at Roswell Park cancer center soon (it will examine Ampligen in combination with interferon alfa-2b in cancer patients with COVID-19). Ampligen has also been shipped to Japan where it will be used in a test as a potential vaccine adjuvant for COVID-19. The other companies on Thursday’s roster include Heat Biologics Inc (NASDAQ:HTBX), Avalon GloboCare Corp (NASDAQ:AVCO), Oregenisis Inc (NASDAQ:ORGS), ImmunoPrecise Antibodies Ltd (CVE:IPA, OTCQB:IPATF).